Emerald Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

Emerald Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-8,726	Closed	-$762K	–	253
2024 Q1	$762K	Sell	8,726 -5,724	-40%	-$512K	0.03%	157
2023 Q4	$1.39M	Buy	14,450 +1,908	+15%	+$169K	0.06%	137
2023 Q3	$1.11M	Buy	12,542 +1,978	+19%	+$176K	0.05%	141
2023 Q2	$916K	Buy	10,564 +1,768	+20%	+$166K	0.04%	148
2023 Q1	$855K	Sell	8,796 -49	-0.6%	-$5.08K	0.04%	150
2022 Q4	$915K	Buy	+8,845	New	+$830K	0.04%	141

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Emerald Advisers's BMRN Position: Q2 2024 in Review

Emerald Advisers sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2024, closing a stake of 8,726 shares — an estimated $762K sold.

Emerald Advisers first reported a position in BMRN in Q4 2022 and held it in 6 quarters. The position peaked at $1.39M in Q4 2023. 558 funds tracked by Wall St. Rank hold BMRN as of Q2 2024.

Emerald Advisers reported no remaining BioMarin Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Emerald Advisers sold 8,726 BioMarin Pharmaceuticals shares in Q2 2024, an estimated $762K.
Emerald Advisers first reported a position in BioMarin Pharmaceuticals in Q4 2022 and held it in 6 quarters.
Emerald Advisers's BioMarin Pharmaceuticals position peaked at $1.39M in Q4 2023.
558 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2024.

Based on Emerald Advisers's 13F filing for Q2 2024, filed 6 Aug 2024.